Wealth Enhancement Trust Services’s Celldex Therapeutics CLDX Stock Holding History

Wealth Enhancement Trust Services’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$893	Buy	+24	New	+$775	﹤0.01%	1149

Other funds holding CLDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wealth Enhancement Trust Services's CLDX Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 24 shares worth $893. The stake represents ﹤0.01% of the portfolio and ranks #1149 among its holdings.

130 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Wealth Enhancement Trust Services held 24 shares of Celldex Therapeutics worth $893 as of Q2 2026.
Celldex Therapeutics was a new Wealth Enhancement Trust Services position in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1149 holding.
130 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.